BR112022014397A2 - Compostos co-agonistas de gip/glp1 - Google Patents

Compostos co-agonistas de gip/glp1

Info

Publication number
BR112022014397A2
BR112022014397A2 BR112022014397A BR112022014397A BR112022014397A2 BR 112022014397 A2 BR112022014397 A2 BR 112022014397A2 BR 112022014397 A BR112022014397 A BR 112022014397A BR 112022014397 A BR112022014397 A BR 112022014397A BR 112022014397 A2 BR112022014397 A2 BR 112022014397A2
Authority
BR
Brazil
Prior art keywords
compounds
gip
glp1
relates
present
Prior art date
Application number
BR112022014397A
Other languages
English (en)
Inventor
Alsina-Fernandez Jorge
Andrew Brown Robert
Chadwick Cummins Robert
Elsayed Hamed Elsayed Mohamed
Renee GEISER Andrea
Lai Xianyin
Qu Hongchang
Morgan Watson Brian
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112022014397A2 publication Critical patent/BR112022014397A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2235—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSTOS COAGONISTAS DE GIP/GLP1. A presente invenção refere-se a compostos tendo atividade tanto nos receptores do polipeptídeo insulinotrópico dependente de glicose humano (GIP) quanto do peptídeo semelhante ao glucagon 1 (GLP-1). A presente invenção também refere-se a compostos tendo uma duração prolongada da ação em cada um destes receptores. Além disso, a presente invenção refere-se a compostos que podem ser administrados por via oral. Estes compostos podem ser úteis no tratamento de diabetes mellitus tipo 2 ("T2DM"). Estes compostos podem ser úteis no tratamento de obesidade.
BR112022014397A 2020-01-23 2021-01-21 Compostos co-agonistas de gip/glp1 BR112022014397A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062964932P 2020-01-23 2020-01-23
PCT/US2021/014302 WO2021150673A1 (en) 2020-01-23 2021-01-21 Gip/glp1 co-agonist compounds

Publications (1)

Publication Number Publication Date
BR112022014397A2 true BR112022014397A2 (pt) 2022-10-11

Family

ID=74592824

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022014397A BR112022014397A2 (pt) 2020-01-23 2021-01-21 Compostos co-agonistas de gip/glp1

Country Status (13)

Country Link
US (1) US20230265151A1 (pt)
EP (1) EP4093757A1 (pt)
JP (1) JP2023511441A (pt)
KR (1) KR20220131292A (pt)
CN (1) CN115298207A (pt)
AR (1) AR121093A1 (pt)
AU (1) AU2021211451B2 (pt)
BR (1) BR112022014397A2 (pt)
CA (1) CA3165430A1 (pt)
IL (1) IL294955A (pt)
MX (1) MX2022009149A (pt)
TW (1) TWI770781B (pt)
WO (1) WO2021150673A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
JP2024508745A (ja) * 2021-02-17 2024-02-28 イーライ リリー アンド カンパニー Ｇｉｐ／ｇｌｐ１デュアルアゴニスト治療方法
CN117586373A (zh) * 2022-08-10 2024-02-23 成都奥达生物科技有限公司 一种长效双激动剂化合物
CN116023444B (zh) * 2022-08-12 2023-08-01 重庆宸安生物制药有限公司 一种gip和glp-1双受体激动剂多肽化合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR080592A1 (es) * 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
EP2718317B1 (en) * 2011-06-10 2018-11-14 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
EA028665B1 (ru) 2012-05-03 2017-12-29 Зилэнд Фарма А/С Соединения - двойные агонисты gip-glp-1 и способы
JP2016503771A (ja) * 2012-12-21 2016-02-08 サノフイ エキセンジン−４誘導体
MX2016005556A (es) * 2013-11-06 2016-07-15 Zealand Pharma As Compuestos agonistas duales de gip-glp-1 y procedimientos.
JOP20200119A1 (ar) * 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
TWI700291B (zh) * 2015-06-22 2020-08-01 美國禮來大藥廠 升糖素及glp-1共激動劑化合物
TWI810937B (zh) * 2017-12-21 2023-08-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途

Also Published As

Publication number Publication date
AU2021211451B2 (en) 2023-11-02
AU2021211451A1 (en) 2022-08-18
TWI770781B (zh) 2022-07-11
KR20220131292A (ko) 2022-09-27
JP2023511441A (ja) 2023-03-17
US20230265151A1 (en) 2023-08-24
AR121093A1 (es) 2022-04-20
IL294955A (en) 2022-09-01
MX2022009149A (es) 2022-12-15
EP4093757A1 (en) 2022-11-30
CN115298207A (zh) 2022-11-04
WO2021150673A1 (en) 2021-07-29
CA3165430A1 (en) 2021-07-29
TW202140528A (zh) 2021-11-01

Similar Documents

Publication Publication Date Title
BR112022014397A2 (pt) Compostos co-agonistas de gip/glp1
ECSP21004913A (es) Compuestos coagonistas de gip/glp1
Williams et al. Drug therapy in obesity: a review of current and emerging treatments
Sharma et al. Recent updates on GLP-1 agonists: Current advancements & challenges
Rehfeld The origin and understanding of the incretin concept
Mehta et al. Liraglutide for weight management: a critical review of the evidence
Van Gaal et al. Weight management in type 2 diabetes: current and emerging approaches to treatment
BR0213377A (pt) mìmico de peptìdeo semelhante ao glucagon 1 humano e seu uso no tratamento de diabetes e condições relacionadas
DE60327771D1 (de) Glp-1 und behandlungsmethode für diabetes
HUP0104574A2 (hu) GLP-1 analógok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
JP2008501765A (ja) Ｇｌｐ−１アゴニストを用いた薬剤誘発性肥満の中和
MX2021012277A (es) Agonista multireceptor y uso medico del mismo.
PE20220938A1 (es) Compuestos agonistas de gipr
EA201370099A1 (ru) Терапия на основе лигандов хемосенсорных рецепторов
JP2014504588A5 (pt)
Unger Rationale use of GLP-1 receptor agonists in patients with type 1 diabetes
Das et al. Contemporary updates on the physiology of glucagon like peptide-1 and its agonist to treat type 2 diabetes mellitus
Agius et al. GLP-1 analogues in clinical management of obesity
MX2023000403A (es) Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del peptido insulinotropico dependiente de glucosa (gip).
BR112022023834A2 (pt) Composto duplo-agonista para os receptores de glp-1 e gip e aplicação do mesmo
Nikkar et al. Review of the mechanism and function of glucagon-like peptide 1 (GLP-1) and GLP-1 receptor agonists in the improvement of type 2 diabetes
Siddhanta New Kid on the Block: Semaglutide
EA202092891A1 (ru) Соединения-коагонисты gip/glp1
Mittal et al. PIONEER PLUS: An Opportunity Knocking the Door for the Management of Diabesity
Banzal et al. Journal of Diabetes, Obesity & Metabolism